"Clinical studies are the key to gaining new knowledge about the diagnosis and treatment of diseases. We're proud to be contributing to this effort in Switzerland."

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

first-in-class medicines approved in Switzerland since 2000

(as of: 03/2020)

25

average number of clinical studies in Switzerland per year

(as of: 03/2020)

95

million Swiss francs invested in research since 2012

(as of: 03/2020)

MSD Switzerland's clinical research is coordinated at our site in the Citybay building in Lucerne.
Our sites

MSD's clinical study program in Switzerland is broadly diversified (as of 03/2020)

Ongoing clinical studies of MSD in Switzerland (as of: 03/2020)

(published on www.clinicaltrials.gov)

Ongoing clinical studies of MSD in Switzerland in the field of infectiology (as of: 03/2020)

Study

Study center

HIV

MK-1439A-021 - recruitment closed
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected

Geneva, Lausanne, Zurich

MK-1439A-024 - recruitment closed
A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Bern, Lausanne, Zurich

MK-8591A-017 - still recruiting
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Basel, Bern, Geneva, Lugano, St. Gallen, Zurich

Ongoing clinical studies of MSD in Switzerland in the field of oncology (as of: 03/2020)

Study

Study center

B-cell lymphoma

MK-3475-170/KEYNOTE 170 - recruitment closed
A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)

Bellinzona

Bladder Cancer

MK-3475-676/KEYNOTE-676 - still recruiting
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Basel, Geneva, Zurich

Colorectal Carcinoma

MK-3475-177/KEYNOTE-177 - recruitment closed
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Geneva, Zurich

Head and Neck Cancer

MK-3475-040/KEYNOTE-040 - will be closed shortly
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Bern, Geneva, Lucerne

MK-3475-048/KEYNOTE-048 - will be closed shortly
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Basel, Zurich, Lausanne

MK-3475-689/KEYNOTE-689 - still recruiting
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Bellinzona, Geneva, Zurich

Liver Cancer

MK-3475-859/KEYNOTE-937 - still recruiting
A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Basel, Bern, Geneva, Lausanne, St.Gallen, Zurich

Lung Cancer

MK-3475-042/KEYNOTE-042 - will be closed shortly
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Basel, Bern, Freiburg

MK-3475-091/KEYNOTE-091 - outsourced
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich

MK-3475-495/KEYNOTE-495 - still recruiting
KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Basel, Chur, Geneva, St. Gallen, Zurich

MK-3475-604/KEYNOTE-604 - recruitment closed
A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Lausanne, Zurich

MK-3475/KEYNOTE-654-04/ECHO-305-04 - will be closed shortly
A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Bern, Geneva, Winterthur, Zurich

MK-3475-859/KEYNOTE-867 - still recruiting
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)

Geneva, Zurich

Melanoma

MK-3475-U02A - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - refractory

Lausanne, Zurich

MK-3475-U02B - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - 1st line

Lausanne, Zurich

MK-3475-U02C - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - neoadjuvant

Lausanne, Zurich

MK-3475-054 / KEYNOTE-054 - outsourced
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Geneva, Lausanne, St. Gallen, Zurich

MK-3475-716/KEYNOTE-716 - still recruiting
Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich

MK-7902-003 - still recruiting
A Phase III, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Basel, Chur, Lausanne, Zurich

Prostate Cancer

MK-3475-199/KEYNOTE-199 - recruitment closed
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Basel, Chur, Lucerne, St. Gallen

MK-3475-991 / Keynote 991 - still recruiting
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Chur, Lausanne, St. Gallen, Zurich

Solid Tumors

MK-3475-587/KEYNOTE-587 - recruitment closed
Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Zurich

MK-7339-002 - still recruiting
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Bellinzona, Geneva, Zurich

MK-8353-014 - still recruiting
Phase 1 b Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors

Bellinzona

Stomach Cancer

MK-3475-062/KEYNOTE-062 - will be closed shortly
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Basel, Bern, Chur, Lausanne, Zurich

MK-3475-859/KEYNOTE-859 - still recruiting
A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Basel, Bellinzona, Chur, Geneva, Lucerne, St.Gallen, Zurich

Click here for an overview of Switzerland-wide studies that are seeking participants www.kofam.ch

We strive to provide hope to people with cancer

We invest in the development of innovative oncological drugs to provide hope to people with cancer.

Learn more

CH-NON-00136, 03/2020